Comparative investigation of the in vitro inhibitory potencies of 13-epimeric estrones and D-secoestrones towards 17β-hydroxysteroid dehydrogenase type 1

References

• Moeller G, Adamski J. Integrated view on 17beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2009;301:7–19
   PubMed Web of Science ®Google Scholar
• Marchais-Oberwinkler S, Henn C, Möller G, et al 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development. J Steroid Biochem Mol Biol 2011;125:66–82
   PubMed Web of Science ®Google Scholar
• Moeller G, Adamski J. Multifunctionality of human 17beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2006;248:47–55
   PubMed Web of Science ®Google Scholar
• Luu-The V, Zhang Y, Poirier D, Labrie F. Characteristics of human types 1, 2 and 3, 17beta-hydroxysteroid dehydrogenase activities: oxidation/reduction and inhibition. J Steroid Biochem Mol Biol 1995;55:581–7
   PubMed Web of Science ®Google Scholar
• Jin JZ, Lin SX. Human estrogenic 17beta-hydroxysteroid dehydrogenase: predominance of estrone reduction and its induction by NADPH. Biochem Biophys Res Commun 1999;259:489–93
   PubMed Web of Science ®Google Scholar
• Negri M, Recanatini M, Hartmann RW. Insights in 17beta-HSD1 enzyme kinetics and ligand binding by dynamic motion investigation. PLoS One 2010;5:e12026
   PubMedGoogle Scholar
• Puranen T, Poutanen M, Ghosh D, et al Origin of substrate specificity of human and rat 17beta-hydroxysteroid dehydrogenase type 1, using chimeric enzymes and site-directed substitutions. Endocrinology 1997;138:3532–9
   PubMed Web of Science ®Google Scholar
• Martel C, Rhéaume E, Takahashi M, et al Distribution of 17 beta-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues. J Steroid Biochem Mol Biol 1992;41:597–603
   PubMed Web of Science ®Google Scholar
• Poirier D. Inhibitors of 17beta-hydroxysteroid dehydrogenases. Curr Med Chem 2003;10:453–77
   PubMed Web of Science ®Google Scholar
• Day JM, Tutill HJ, Purohit A, Reed MJ. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. Endocr Relat Cancer 2008;15:665–92
   PubMed Web of Science ®Google Scholar
• Poirier D. 17beta-Hydroxysteroid dehydrogenase inhibitors: a patent review. Expert Opin Ther Pat 2010;20:1123–45
   PubMed Web of Science ®Google Scholar
• Brozic P, Lanisnik Risner T, Gobec S. Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. Curr Med Chem 2008;15:137–50
   PubMed Web of Science ®Google Scholar
• Stander A, Joubert F, Joubert A. Docking, synthesis and in vivo evaluation of antimitotic estrone analogs. Chem Biol Drug Res 2011;77:173–81
   PubMed Web of Science ®Google Scholar
• Leese MP, Leblond B, Newman SP, et al Anti-cancer activities of novel d-ring modified 2-substituted estrogen-3-O-sulfamates. J Steroid Biochem Mol Biol 2005;94:239–51
   PubMed Web of Science ®Google Scholar
• Agoston GE, Shah JH, LaVallee TM, et al Synthesis and structure–activity relationships of 16-modified analogs of 2-methoxyestradiol. Bioorg Med Chem 2007;15:7524–37
   PubMed Web of Science ®Google Scholar
• Shah JH, Agoston GE, Suwandi L, et al Synthesis of 2- and 17-substituted estrone analogs and their antiproliferative structure–activity relationships compared to 2-methoxyestradiol. Bioorg Med Chem 2009;17:7344–52
   PubMed Web of Science ®Google Scholar
• Gupta A, Kumar SB, Negi AS. Current status on development of steroids as anticancer agents. J Steroid Biochem Mol Biol 2013;137:242–70
   PubMed Web of Science ®Google Scholar
• Schönecker B, Lange C, Kötteritzsch M, et al Conformational design for 13alpha-steroids. J Org Chem 2000;65:5487–97
   PubMed Web of Science ®Google Scholar
• Jovanovic-Santa S, Petrovic J, Andric S, et al Synthesis, structure, and screening of estrogenic and antiestrogenic activity of new 3,17-substituted-16,17-seco-estratriene derivatives. Bioorg Chem 2003;31:475–84
   PubMed Web of Science ®Google Scholar
• Ayan D, Roy J, Maltais R, Poirier D. Impact of estradiol structural modifications (18-methyl and/or 17-hydroxy inversion of configuration) on the in vitro and in vivo estrogenic activity. J Steroid Biochem 2011;127:324–30
   Google Scholar
• Szabó J, Bacsa I, Wölfling J, et al Synthesis and in vitro pharmacological evaluation of N-[(1-benzyl-1,2,3-triazol-4-yl)methyl]-carboxamides on d-secoestrone scaffolds. J Enzyme Inhib Med Chem 2016;31:574–9
   PubMed Web of Science ®Google Scholar
• Bacsa I, Jójárt R, Schneider G, et al Synthesis of A-ring halogenated 13alpha-estrone derivatives as potential 17beta-HSD1 inhibitors. Steroids 2015;104:230–6
   PubMed Web of Science ®Google Scholar
• Tremblay MR, Poirier D. Overview of a rational approach to design type I 17beta-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: chemical synthesis and biological evaluation J Steroid Biochem Mol Biol 1998;66:179–91
   PubMed Web of Science ®Google Scholar
• Ghosh D, Pletnev VZ, Zhu DW, et al Structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase at 2.20 A resolution. Structure 1995;3:503–13
   PubMed Web of Science ®Google Scholar
• Ghosh D, Vihko P. Molecular mechanisms of estrogen recognition and 17-keto reduction by human 17beta-hydroxysteroid dehydrogenase 1. Chem Biol Interact 2001;130–132:637–50
   PubMed Web of Science ®Google Scholar
• Sawicki MW, Erman M, Puranen T, et al Structure of the ternary complex of human 17beta-hydroxysteroid dehydrogenase type 1 with 3-hydroxyestra-1,3,5,7-tetraen-17-one (equilin) and NADP+. Proc Natl Acad Sci USA 1999;96:840–5
   PubMed Web of Science ®Google Scholar
• Breton R, Housset D, Mazza C, Fontecilla-Camps JC. The structure of a complex of human 17beta-hydroxysteroid dehydrogenase with estradiol and NADP + identifies two principal targets for the design of inhibitors. Structure 1996;4:905–15
   PubMed Web of Science ®Google Scholar
• Filling C, Berndt KD, Benach J, et al Critical residues for structure and catalysis in short-chain dehydrogenases/reductases. J Biol Chem 2002;277:25677–84
   PubMed Web of Science ®Google Scholar
• Gangloff A, Garneau A, Huang YW, et al Human oestrogenic 17beta-hydroxysteroid dehydrogenase specificity: enzyme regulation through an NADPH-dependent substrate inhibition towards the highly specific oestrone reduction. Biochem J 2001;356:269–76
   PubMed Web of Science ®Google Scholar
• Mazza C, Breton R, Housset D, Fontecilla-Camps JC. Unusual charge stabilization of NADP + in 17beta-hydroxysteroid dehydrogenase. J Biol Chem 1998;273:8145–52
   PubMed Web of Science ®Google Scholar
• Penning TM. Molecular endocrinology of hydroxysteroid dehydrogenases. Endocr Rev 1997;18:281–305
   PubMed Web of Science ®Google Scholar
• Ma H, Ratnam K, Penning TM. Mutation of nicotinamide pocket residues in rat liver 3 alpha-hydroxysteroid dehydrogenase reveals different modes of cofactor binding. Biochemistry 2000;39:102–9
   PubMed Web of Science ®Google Scholar
• Han Q, Campbell RL, Gangloff A, et al Dehydroepiandrosterone and dihydrotestosterone recognition by human estrogenic 17beta-hydroxysteroid dehydrogenase. C-18/c-19 steroid discrimination and enzyme-induced strain. J Biol Chem 2000;275:1105–11
   PubMed Web of Science ®Google Scholar
• Srungboonmee K, Songtawee N, Monnor T, et al Probing the origins of 17β-hydroxysteroid dehydrogenase type 1 inhibitory activity via QSAR and molecular docking. Eur J Med Chem 2015;96:231–7
   PubMed Web of Science ®Google Scholar
• Sam KM, Boivin RP, Tremblay MR, et al C16 and C17 derivatives of estradiol as inhibitors of 17 beta-hydroxysteroid dehydrogenase type 1: chemical synthesis and structure–activity relationships. Drug Des Discov 1998;15:157–80
   PubMedGoogle Scholar
• Inano H, Tamaoki B. Affinity labeling of arginyl residues at the catalytic region of estradiol 17 beta-dehydrogenase from human placenta by 16-oxoestrone. Eur J Biochem 1983;129:691–5
   PubMedGoogle Scholar
• Pelletier JD, Poirier D. Synthesis and evaluation of estradiol derivatives with 16 alpha-(bromoalkylamide), 16 alpha-(bromoalkyl) or 16 alpha-(bromoalkynyl) side chain as inhibitors of 17 beta-hydroxysteroid dehydrogenase type 1 without estrogenic activity. Bioorg Med Chem 1996;4:1617–28
   PubMed Web of Science ®Google Scholar
• Butenandt A, Wolff A, Karlson P. Über Lumi-oestron. Chem Ber 1941;74:1308–12
   Google Scholar
• Maltais R, Trottier A, Barbeau X, et al Impact of structural modifications at positions 13, 16 and 17 of 16β-(m-carbamoylbenzyl)-estradiol on 17β-hydroxysteroid dehydrogenase type 1 inhibition and estrogenic activity. J Steroid Biochem Mol Biol 2016;161:24–35
   PubMed Web of Science ®Google Scholar
• Mernyák E, Huber J, Benedek G, et al Electrophile- and Lewis acid-induced nitrone formation and 1,3-dipolar cycloaddition reactions in the 13α- and 13β-estrone series. Arkivoc 2010;xi:101–13
   Google Scholar
• Tanaka N, Nonaka T, Nakanishi M, et al Crystal structure of the ternary complex of mouse lung carbonyl reductase at 1.8 A resolution: the structural origin of coenzyme specificity in the short-chain dehydrogenase/reductase family. Structure 1996;4:33–45
   PubMed Web of Science ®Google Scholar
• Persson B, Kallberg Y, Oppermann U, Jörnvall H. Coenzyme-based functional assignments of short-chain dehydrogenases/reductases (SDRs). Chem Biol Interact 2003;143–144:271–8
   PubMed Web of Science ®Google Scholar
• Blomquist CH. Kinetic analysis of enzymic activities: prediction of multiple forms of 17 beta-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol 1995;55:515–24
   PubMed Web of Science ®Google Scholar
• Huang YW, Pineau I, Chang HJ, et al Critical residues for specificity toward NADH or NADPH in human estrogenic 17β-hydroxysteroid dehydrogenase: site-directed mutagenesis designed from the three-dimensional structure of the enzyme. Mol Endocrinol 2001;15:2010–20
   PubMed Web of Science ®Google Scholar
• Agarwal AK, Auchus RJ. Minireview: cellular redox state regulates hydroxysteroid dehydrogenase activity and intracellular hormone potency. Endocrinology 2005;146:2531–8
   PubMed Web of Science ®Google Scholar
• Sherbet DP, Papari-Zareei M, Khan N, et al Cofactors, redox state, and directional preferences of hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2007;265–266:83–8
   PubMed Web of Science ®Google Scholar
• Fournier D, Poirier D, Mazumdar M, Lin SX. Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives. Eur J Med Chem 2008;43:2298–306
   PubMed Web of Science ®Google Scholar
• Marchais-Oberwinkler S, Frotscher M, Ziegler E, et al Structure–activity study in the class of 6-(3′-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors. Mol Cell Endocrinol 2009;301:205–11
   PubMed Web of Science ®Google Scholar
• Kruchten P, Werth R, Marchais-Oberwinkler S, et al Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agents. Mol Cell Endocrinol 2009;301:154–7
   PubMed Web of Science ®Google Scholar
• Farhane S, Fournier MA, Poirier D. Chemical synthesis, characterisation and biological evaluation of lactonic-estradiol derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 1. Mol Cell Endocrinol 2009;137:322–31
   Google Scholar
• Mernyak E, Szabo J, Huber J, et al Synthesis and antiproliferative effects of d-homo- and d-secoestrones. Steroids 2014;87:128–36
   PubMed Web of Science ®Google Scholar
• Mernyak E, Fiser G, Szabo J, et al Synthesis and in vitro antiproliferative evaluation of d-secooxime derivatives of 13β- and 13α-estrone. Steroids 2014;89:47–55
   PubMed Web of Science ®Google Scholar